Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
MLLT6
REST API REST API
Homo sapiens
MLLT6 is differentially expressed in 202 experiments: 97 organism parts: cerebellum, liver, ... (95 more);, 106 disease states: normal, control, ... (104 more);, 75 cell types 359 cell lines 29 compound treatments and 56 other conditions.
Synonyms FLJ23480, AF17
Orthologs F1M2H7_RAT (Rattus norvegicus)   MLLT6 (Bos taurus)   Mllt6 (Mus musculus)   ENSCING00000004441 (Ciona intestinalis)   rno (Drosophila melanogaster)   MLLT6 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term protein binding, regulation of transcription, DNA-dependent, metal ion binding, nucleus, zinc ion binding
InterPro Term Znf_PHD-finger, Znf_PHD
UniProt Accession P55198, E9PEP1
Search EB-eye ENSG00000108292
Show more properties
Experimental Factors
Organism part

studied in E-AFMX-5, E-GEOD-6573, E-GEOD-22541, E-GEOD-6919, E-GEOD-3526, ... (16 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-19639, E-GEOD-4219, E-GEOD-3202, E-GEOD-6013, ... (26 experiments)

Factor Value U/D Experiments
HepG2
3
E-GEOD-21154, E-MTAB-37, E-GEOD-7307
MCF-7
3
E-GEOD-20081, E-GEOD-19639, E-GEOD-5823
A549
2
E-GEOD-3202, E-GEOD-6013
CCRFCEM
2
E-MTAB-37, E-GEOD-24147
LNCaP
2
E-GEOD-14990, E-GEOD-14464
U87
2
E-GEOD-20089, E-MEXP-903
353 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-22373, E-GEOD-21668, E-GEOD-20677, E-GEOD-4219, ... (32 experiments)

Factor Value U/D Experiments
human embryonic stem cell
3
E-GEOD-18147, E-GEOD-20033, E-GEOD-18265
monocyte
1
2
E-GEOD-11755, E-GEOD-5099, E-GEOD-22373
spermatocyte
1
E-TABM-130
testis - leydig cell
1
E-AFMX-5
mononuclear
1
E-GEOD-13987
activated natural killer cell
1
E-TABM-702
69 more value(s).


Disease state

studied in E-GEOD-3307, E-MEXP-1922, E-GEOD-6872, E-GEOD-15960, E-MEXP-882, ... (46 experiments)

Factor Value U/D Experiments
control
1
3
E-GEOD-16363, E-GEOD-8121, E-GEOD-21912, E-GEOD-16728
colorectal carcinoma
2
E-GEOD-23878, E-MTAB-37
adrenocortical carcinoma
2
E-TABM-311, E-GEOD-10927
gastric carcinoma
2
E-GEOD-15460, E-MTAB-37
glioblastoma
2
E-GEOD-4290, E-MTAB-37
prostate carcinoma
2
E-MEXP-2034, E-MTAB-37
100 more value(s).


Compound treatment

studied in E-GEOD-5741, E-GEOD-15205, E-TABM-782, E-TABM-868, E-GEOD-5099, ... (18 experiments)

Factor Value U/D Experiments
lipopolysaccharide
2
E-TABM-868, E-MEXP-1958
actinomycin D
1
E-GEOD-6400
HMB-PP (phosphoantigen)
1
1
E-MEXP-1601
unknown
1
E-GEOD-7307
Cxcl12
1
1
E-GEOD-7307
MIG control
1
E-GEOD-15811
23 more value(s).


Age at diagnosis

studied in E-GEOD-3494

Factor Value U/D Experiments
48
2
1
E-GEOD-3494
29
2
1
E-GEOD-3494


Agent
studied in E-GEOD-19519

Biosource provider
studied in E-MTAB-37, E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-GEOD-21589, E-GEOD-16363, E-GEOD-21610 ... (5 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-21589, E-GEOD-16363, E-GEOD-18995, ... (6 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-GEOD-20033, E-MEXP-2359

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-GEOD-21138

Erbb2
studied in E-GEOD-21653

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-1643

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-MEXP-1482, E-GEOD-7578, E-GEOD-17385, ... (7 experiments)

Genotype
studied in E-TABM-1029, E-GEOD-17476, E-MEXP-421, E-TABM-868, E-TABM-601, ... (8 experiments)

Growth condition
studied in E-TABM-127, E-GEOD-20504, E-GEOD-10315, E-MEXP-1741, E-MEXP-2146 ... (5 experiments)

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276

Individual
studied in E-MTAB-197, E-TABM-325, E-MEXP-1290, E-MEXP-2069, E-TABM-666, ... (17 experiments)

Infection
studied in E-GEOD-12108

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214, E-GEOD-12662

Lymph node status
studied in E-GEOD-6532

Media
studied in E-MEXP-765

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-19703, E-GEOD-1460, E-GEOD-17636

Population
studied in E-MTAB-197, E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-19445, E-GEOD-19246

Replicate
studied in E-GEOD-18791, E-GEOD-10896

Rna integrity
studied in E-TABM-325

RNAi
studied in E-MEXP-2115, E-MEXP-1857, E-MEXP-2759

Sample preparation
studied in E-GEOD-16728

Sample type
studied in E-TABM-783

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-17400

Sex
studied in E-GEOD-1643, E-GEOD-19743, E-GEOD-19069, E-GEOD-22541, E-GEOD-7307 ... (5 experiments)

Stimulation
studied in E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Test result
studied in E-TABM-276

Tissue
studied in E-GEOD-30573

Treatment
studied in E-GEOD-16837, E-MEXP-973, E-GEOD-19246, E-GEOD-21912, E-GEOD-19136, ... (7 experiments)

Tumor grading
studied in E-GEOD-4290

Tumor size
studied in E-GEOD-3494, E-GEOD-4922

Processing time: 0.412 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM